Physician profile
Shuo Li
NPI 1871926899
$22,533.32
in general payments reported to CMS, 2019-2025
9 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $17.41 · 2021: $16.81 · 2022: $1,347 · 2023: $804 · 2024: $265 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,500.00 |
| Food and Beverage | $1,270.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $18,550.67 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Inari Medical, INC. | $1,529.67 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic Vascular, INC. | $1,398.29 | 2019-2020 | |
| Angiodynamics, INC. | $797.48 | 2022-2024 | Alphavac, Nanoknife, Solero |
| Penumbra, INC. | $97.78 | 2025 | Indigo System, Ruby Coil |
| Merck Sharp & Dohme LLC | $53.24 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Boston Scientific Corporation | $44.81 | 2023 | |
| Allergan, INC. | $27.93 | 2022 | |
| Abbott Laboratories | $16.64 | 2024 | Perclose Prostyle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuo Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.